The abstract is read at the publisher; the summary is JClub's.
TPH1-driven serotonin metabolism stabilizes the neuroendocrine prostate cancer plastic state by enabling serotonin-based posttranslational serotonylation of mTOR and activating FOXM1/E2F1.
- Why it matters: Advanced prostate cancer often escapes androgen receptor pathway inhibition, and NEPC’s metabolic rewiring has been less defined than its transcriptional and epigenetic changes.
- What they did: Wei et al. showed that serotonin metabolism regulated by tryptophan hydroxylase 1 (TPH1) supports serotonylation-dependent mTOR regulation and FOXM1/E2F1 activation in NEPC.
- The result: TPH1 emerges as both a neuroendocrine marker and a functional mediator of hormone therapy resistance, suggesting TPH1 targeting could delay or reverse therapy-induced NEPC in selected patients.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.